Introduction	Objectives
Study Design	Recruitment of cases
Lipid Clinics Participating in the study	Follow-up
What is being measured?	Surveys Safeheart

The general objectives of this project are:

• 1) to determine the absolute and relative mortality from all causes and from cardiovascular disease in treated FH patients.
• 2) to analyse the relative risk of non-fatal cardiovascular events in this population
• 3) to study the prognostic role of classic risk factors, dietary habits and genetic variability associated with favourable or unfavourable evolution in FH clinical expression.
• 4) to analyse the role of LDL-r mutation types in determining the risk of coronary disease.
• 5) To estimate the long-term quality of life of FH subjects and their families.